source
- Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutidegRoche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…
- Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug marketThe American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…